Edner et al. [97] demonstrated that the expression of the immunomodulatory markers ICOS and PD-1 on T follicular helper cells predicted the clinical response, as measured by C-peptide, in abatacept-treated T1D patients, which could help select patients that are the most likely to respond to this drug. The gene discussed is ICOS; the disease is type 1 diabetes mellitus.